Skip to main content

Tazemetostat Dosage

Medically reviewed by Drugs.com. Last updated on Feb 22, 2024.

Applies to the following strengths: 200 mg

Usual Adult Dose for Soft Tissue Sarcoma

800 mg orally twice daily

Duration: Until disease progression or unacceptable toxicity.

Uses:
For the treatment of adult patients with, metastatic or locally advanced epithelioid sarcoma not eligible for complete resection

Usual Adult Dose for Follicular Lymphoma

800 mg orally twice daily

Duration: Until disease progression or unacceptable toxicity.

Comment:
Select patients with relapsed or refractory (R/R) follicular lymphoma (FL) based on the presence of EZH2 mutation.

Uses:
For the treatment of adult patients with, relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and who have received at least 2 prior systemic therapies or who have no satisfactory alternative treatment options

Usual Pediatric Dose for Soft Tissue Sarcoma

16 years and older:
800 mg orally twice daily

Duration: Until disease progression or unacceptable toxicity.

Use: For the treatment of pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection

Renal Dose Adjustments

Mild, moderate, severe, or end stage renal impairment: No adjustment recommended.

Liver Dose Adjustments

Mild (total bilirubin greater than 1 to 1.5 times the upper limit of normal [ULN] or AST greater than ULN) hepatic impairment: No adjustment recommended.
Moderate (total bilirubin greater than 1.5 to 3 x ULN) or severe (total bilirubin greater than 3 times ULN) hepatic impairment: Data not available

Dose Adjustments

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:


DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
NEUTROPENIA:
Neutrophil count less than 1 x 10(9)/L:
THROMBOCYTOPENIA:
Platelet count less than 50 x 10(9)/L:
ANEMIA:
Hemoglobin less than 8 g/dL:
OTHER ADVERSE REACTIONS:
Grade 3:
Grade 4:

DOSAGE MODIFICATIONS FOR DRUG INTERACTIONS:
Strong and Moderate CYP450 3A Inhibitors:

RECOMMENDED DOSE REDUCTIONS OF THIS DRUG FOR MODERATE CYP450 3A INHIBITORS:

Precautions

CONTRAINDICATIONS:


Safety and efficacy have not been established in patients younger than 16 years for epithelioid sarcoma.
Safety and efficacy have not been established in patients younger than 18 years for relapsed or refractory follicular lymphoma.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


General:
Use of this drug is approved under accelerated approval based on overall response rate and duration of response.

Storage requirements:

Monitoring:
Oncologic: Secondary malignancies

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.